Xemed is a product focused diagnostic drug company with broad expertise and IP in the field of hyperpolarized gas MRI. The firm is set up to partner with clinical researchers, the pharmaceutical industry, and NIH to advance pulmonary functional imaging through the regulatory approval process towards commercialization. Xemed collaborates with academic partners throughout its MagniXene® Imaging Network to refine its technologies and to assess safety and efficacy of pulmonary functional imaging applications in disease management and drug development X, Pulmonary functional imaging with MagniXene® can provide a foundation for a new era of personalized care in respiratory diseases. A new category of minimally-invasive procedures and conformal therapies will be able to benefit from image guidance from 3D maps of lung functional microstructure. With a focus is on COPD, asthma, and cancer, the judgment of management is that MagniXene® may play many roles in patient care: evaluating antibiotic wash-out treatment in children with cystic fibrosis exacerbations, evaluating impairment of oxygen uptake due to pulmonary emboli pre- and post-endarterectomy, and providing early signs of bronchiolitis obliterans in lung transplant tissue rejection